<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387917</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 65/16</org_study_id>
    <nct_id>NCT03387917</nct_id>
  </id_info>
  <brief_title>TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors</brief_title>
  <official_title>TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TLD-1 is a novel liposomal formulation of doxorubicin (PEG surface) that compared favorably&#xD;
      to conventional liposomal formulations of doxorubicin including Caelyx® in preclinical in&#xD;
      vivo models. Particle features including size, charge distribution, lipid composition and&#xD;
      drug release add up to a considerably altered particle behavior compared to Caelyx®,&#xD;
      potentially explaining the lack of hand-foot-syndrome in respective animal models.&#xD;
      Preclinical evaluation confirmed TLD-1 to be a promising new and innovative formulation of&#xD;
      doxorubicin with promising activity and good tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite impressive progress in the fields of surgical and immunological cancer therapies,&#xD;
      most late-stage cancer treatments still heavily depend on conventional chemotherapeutics,&#xD;
      which are often effective but also toxic, resulting in severe adverse effects limiting the&#xD;
      dose and duration of therapy. Consequently, there remains a high unmet medical need for new&#xD;
      innovative systemic treatments with an improved risk-benefit-profile.&#xD;
&#xD;
      Doxorubicin is a potent anthracycline used as a systemic treatment against several solid&#xD;
      tumor including breast, ovarian and bladder cancer, small cell lung cancer and various types&#xD;
      of sarcoma. However, Doxorubicin use is often limited due to hematological and&#xD;
      non-hematological toxicity including cumulative cardiotoxicity with myocardial damage.&#xD;
&#xD;
      Cardiotoxicity has been substantially mitigated through the introduction of liposomal&#xD;
      formulations such as Myocet and Caelyx/Doxil. Both products are associated with substantially&#xD;
      lower rates of cardiac dysfunction during or post-treatment. Whereas Myocet's clinical use&#xD;
      remains limited due to the intricate &quot;bedside&quot; reconstitution process, Caelyx has been&#xD;
      associated with a high incidence of Palmar-Plantar Erythrodysesthesia (PPE) (also called&#xD;
      hand-foot-syndrome), likely due to its long plasma half-life.&#xD;
&#xD;
      The development of TLD-1 (Talidox) aimed at combining the cardio-preserving properties of the&#xD;
      liposomal delivery system with shorter blood circulation time in order to reduce the risk of&#xD;
      PPE. Even though the pathophysiology of PPE is not yet fully understood, studies analyzing&#xD;
      the correlation of dose and pharmacokinetic parameters with PLD toxic effects revealed that&#xD;
      the severity of PPE correlated significantly with plasma half-life (t1/2).&#xD;
&#xD;
      Given its performance in preclinical trials, TLD-1 bears the potential for an improved&#xD;
      benefit/risk profile compared to established liposomal doxorubicin formulations including&#xD;
      Caelyx.&#xD;
&#xD;
      This first-in-human phase-I trial will evaluate the safety and will establish the maximal&#xD;
      tolerated dose (MTD) and recommended phase II dose of TLD-1, and characterize specific dose&#xD;
      limiting toxicities (DLT) of TLD-1. Moreover, the trial shall yield information on adverse&#xD;
      events profile, pharmacokinetics and preliminary efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The trial uses an accelerated titration design (ATD) up to the occurrence of the first DLT, followed by a modified continual reassessment method (mCRM) for dose escalation part and randomized cross-over design for the comparative PK part</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>at 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: volume of distribution [Vd]</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Area under curve [AUC]</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Area under curve [Cmax]</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Terminal half life [t½]</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Clearance (CL)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive pharmacokinetics (PK) of TLD-1 vs Caelyx: Ratio of unencapsulated to encapsulated drug over time for Caelyx and TLD-1</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response (OR)</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>at 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetics (PK) of TLD-1: clearance (CL)</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetics (PK) of TLD-1: volume of distribution (Vd)</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetics: Area Under the Curve [AUC]</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetics: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TLD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of treatment&#xD;
1 cycle: 21 days&#xD;
1 cycle: 28 days (only comparative PK part, in cycle 1 or 2)&#xD;
until progression or occurrence of unacceptable toxicity or withdrawal, but&#xD;
maximum 9 cycles for patients previously not treated with anthracyclines&#xD;
maximum 6 cycles for patients previously treated with anthracyclines.&#xD;
Dose: i.v., according to DL on day 1 of each cycle or tentative MTD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caelyx (only for comparative PK part)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of treatment&#xD;
1 cycle: 28 days&#xD;
Caelyx is given only in one cycle (cycle 1 or 2)&#xD;
Dose: i.v., 40mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLD-1</intervention_name>
    <description>TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.</description>
    <arm_group_label>TLD-1</arm_group_label>
    <other_name>Talidox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caelyx</intervention_name>
    <description>Caelyx is a liposomal formulation of the anthracycline doxorubicin</description>
    <arm_group_label>Caelyx (only for comparative PK part)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria for dose escalation part:&#xD;
&#xD;
          -  Final protocol until amendment 2: Patients with either histologically or cytologically&#xD;
             confirmed advanced or recurrent solid tumor who failed standard therapy or for whom no&#xD;
             effective standard therapy is available&#xD;
&#xD;
          -  From Amendment 3 on: Patients with histologically or cytologically confirmed advanced&#xD;
             malignant tumors of the breast, ovary, uterine or sarcoma who failed standard therapy&#xD;
             or for whom no effective standard therapy is available.&#xD;
&#xD;
          -  Patients may have received up to 3 prior lines of palliative systemic chemotherapy&#xD;
&#xD;
          -  Patients with brain metastases must have undergone definitive treatment (surgery&#xD;
             and/or radiation) at least 1 month prior to starting study drug and be documented as&#xD;
             having stable disease by imaging and are on stable doses of steroids for at least 2&#xD;
             weeks.&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function&#xD;
&#xD;
        Key inclusion criteria for comparative PK part:&#xD;
&#xD;
          -  Patients with either histologically or cytologically confirmed advanced or recurrent&#xD;
             breast or ovarian cancer of all histologies&#xD;
&#xD;
               -  Histologically-confirmed ovarian, fallopian tube or primary peritoneal cancer&#xD;
                  (collectively referred to herein as 'ovarian cancer') that is either&#xD;
                  platinum-resistant (disease progression within 6 months of the last receipt of&#xD;
                  platinum-based chemotherapy) or refractory (lack of response or disease&#xD;
                  progression while receiving the most recent platinum-based therapy).&#xD;
&#xD;
               -  Patients with ovarian cancer may have received up to 3 lines of prior cytotoxic&#xD;
                  chemotherapy, but maximum 1 of them in the platinumresistant/ refractory setting.&#xD;
                  Confirmed high-grade serous, endometrioid, or carcinosarcoma histotypes are&#xD;
                  permitted.&#xD;
&#xD;
               -  Patients with advanced or recurrent breast cancer may have received up to 2 prior&#xD;
                  lines of palliative cytotoxic chemotherapy.&#xD;
&#xD;
          -  Patients with brain metastases must have undergone definitive treatment (surgery&#xD;
             and/or radiation) at least 1 month prior to starting study drug and be documented as&#xD;
             having stable disease by imaging and be on stable doses of steroids for at least 2&#xD;
             weeks.&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function&#xD;
&#xD;
        Key exclusion criteria for dose escalation and comparative PK part:&#xD;
&#xD;
          -  Significant cardiac disease or abnormality&#xD;
&#xD;
          -  Patients who have received prior anthracyclines at a cumulative dose that exceeds&#xD;
             250mg/m2 for non-liposomal doxorubicin, 300mg/m2 for liposomal doxorubicin or 400mg/m2&#xD;
             for epirubicin and/or are refractory (during 3 months) to anthracyclines or have&#xD;
             experienced allergic reactions or severe toxicity (grade 3 or 4) under anthracyclines&#xD;
&#xD;
          -  Prior systemic chemotherapy/treatment for adjuvant/metastatic disease, radiotherapy,&#xD;
             immunotherapy, or investigational agents within 28 days 5 half- life periods of&#xD;
             previous therapy before registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dagmar Hess, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anastasios Stathis, MD</last_name>
    <role>Study Director</role>
    <affiliation>IOSI, Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Jörger, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Bärtschi</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasios Stathis, MD</last_name>
      <phone>+41 91 811 89 31</phone>
      <email>anastasios.stathis@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Anastasios Stathis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Bastian, MD</last_name>
      <phone>+41 81 256 68 84</phone>
      <email>sara.bastian@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Sara Bastian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Hess, MD</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>dagmar.hess@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Dagmar Hess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>TLD-1</keyword>
  <keyword>phase I</keyword>
  <keyword>Talidox</keyword>
  <keyword>Liposomal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

